Biocon

FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks
FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks
Endpoints
FDA
Biocon
Viatris
Avastin
biosimilars
drug manufacturing
Flag link:
Takeover-driven resurgence fails to materialize for biotech
Takeover-driven resurgence fails to materialize for biotech
EP Vantage
M&A
AbbVie
Biocon
Biogen
Biohaven
GSK
Halozyme Therapeutics
Samsung Bioepis
UCB
Viatris
Flag link:
Biocon buys Viatris biosimilars for $3.3bn, eyes IPO
Biocon buys Viatris biosimilars for $3.3bn, eyes IPO
Pharmaforum
Biocon
India
Viatris
Mylan
biosimilars
M&A
Flag link:
Viatris launched two versions of its interchangeable insulin biosimilar. Why?
Viatris launched two versions of its interchangeable insulin biosimilar. Why?
Fierce Pharma
Biocon
Viatris
Semglee
insulin
biosimilars
diabetes
Sanofi
Lantus
Flag link:
How This Historic FDA Approval Benefits Viatris
How This Historic FDA Approval Benefits Viatris
Motley Fool
Viatris
Biocon
FDA
Semglee
biosimilars
insulin
diabetes
interchangeable biosimilars
Flag link:
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Center for Biosimilars
Biocon
Mylan
Semglee
generics
insulin
diabetes
biosimilars
Flag link:
Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
Motley Fool
FDA
Mylan
Biocon
Semglee
Sanofi
insulin
Lantus
diabetes
Flag link:
Biocon insulin operation gets FDA nod, paving way for approval of Lantus knockoff
Biocon insulin operation gets FDA nod, paving way for approval of Lantus knockoff
Fierce Pharma
Biocon
insulin
diabetes
Lantus
Mylan
drug manufacturing
Flag link:
Mylan's Lantus copy derailed in U.S. again by manufacturing ills
Mylan's Lantus copy derailed in U.S. again by manufacturing ills
Fierce Pharma
Mylan
Lantus
generics
Biocon
drug manufacturing
diabetes
Flag link:
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
Fierce Pharma
FDA
Biocon
Mylan
Sanofi
Lantus
insulin
drug manufacturing
Flag link:
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Fierce Pharma
Merck
Samsung Bioepis
Lantus
insulin
diabetes
biosimilars
Mylan Labs
Biocon
Flag link:
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
CP Wire
Coherus Biosciences
Neulasta
CHS-1701
Mylan
Biocon
Flag link:
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
Coherus Biosciences
Neulasta
CHS-1701
Mylan
Biocon
Flag link:
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Endpoints
Novartis
Biocon
drug development
biosimilars
Flag link:
FDA Approves Eighth Biosimilar, First for Cancer Drug Herceptin
FDA Approves Eighth Biosimilar, First for Cancer Drug Herceptin
RAPS.org
FDA
biosimilars
Herceptin
Ogivri
Mylan Labs
Biocon
Flag link:
Biocon and Mylan say their plant is good to go as FDA decision nears for their Herceptin copy
Biocon and Mylan say their plant is good to go as FDA decision nears for their Herceptin copy
Fierce Pharma
Biocon
Mylan Labs
FDA
Herceptin
drug manufacturing
biologics
India
Flag link:
Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL
Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL
Fierce Pharma
Mylan Labs
Biocon
Amgen
Neulasta
CRL
FDA
biosimilars
Flag link:
Biocon closer to receiving nod for LatAm entry
Biocon closer to receiving nod for LatAm entry
DNA India, India
Biocon
Flag link:
Roche wins battle against India sales of generic cancer drug
Roche wins battle against India sales of generic cancer drug
FT.com
Roche
India
breast cancer
biosimilars
Biocon
Mylan
Flag link:
Biocon to start selling breast cancer drug in India in February
Biocon to start selling breast cancer drug in India in February
Yahoo/Reuters
Biocon
breast cancer
trastuzumab
generics
Herceptin
Flag link:

Pages